Loading...
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab
Spira, A. Girard, N. Krebs, Matthew Park, K. Shu, C. Dougherty, L. Cho, B. C.
Spira, A.
Girard, N.
Krebs, Matthew
Park, K.
Shu, C.
Dougherty, L.
Cho, B. C.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Other
Citation
Spira A, Girard N, Krebs M, Park K, Shu C, Dougherty L, et al. A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab. Future oncology (London, England). 2023 Oct;19(33):2213-25. PubMed PMID: 39189517. Epub 2024/08/27. eng.